Study may lead to new targeted therapies that inhibit the spread of cancer

For decades, physicians have known that many kinds of cancer cells often spread first to lymph nodes before traveling to distant organs through the bloodstream.

New research from Children's Medical Center Research Institute at UT Southwestern (CRI) provides insight into why this occurs, opening up new targets for treatments that could inhibit the spread of cancer.

The study, published today in Nature, found melanoma cells that pass through the lymph nodes pick up a protective coating, allowing them to survive high levels of oxidative stress in the blood and go on to form distant tumors.

Most cancer deaths happen after cancer spreads to other parts of the body through a process known as metastasis. This occurs when cancer cells from the primary tumor spread through blood vessels or migrate through lymphatic vessels before entering the blood.

Previous research has focused on how cancer cells metastasize through the blood, but very little was known about how these cells compare to cells that metastasize through lymphatics. Our data suggest that passing through the lymphatics can promote the survival and spread of melanoma cells by protecting the cells from the oxidative stress they normally experience during metastasis."

Sean Morrison, PhD., Director and Investigator, CRI, Howard Hughes Medical Institute (HHMI)

The researchers observed how human melanoma cells behaved when injected intravenously or into the lymphatic system of mice. They found that cancer cells injected into lymph nodes had a better chance of surviving and forming tumors than those injected directly into the blood.

Researchers hypothesized this difference could be explained by the high levels of oxidative stress cancer cells experience when they migrate through the blood.

Exposure to oxidative stress in the blood is one reason why metastasis is a very inefficient process in which most cancer cells die before they have an opportunity to grow at a distant site.

"After further analysis, we discovered that the oxidative stress in the blood causes the cancer cells to undergo a specific form of cell death called ferroptosis," says Jessalyn Ubellacker, Ph.D., lead author of the study and a postdoctoral researcher in the Morrison lab.

"In contrast, cancer cells in lymph experience lower levels of oxidative stress and are protected from ferroptosis."

To better understand why melanoma cells undergo ferroptosis in the blood but not the lymph, researchers looked for metabolic differences between cancer cells in the blood versus the lymph.

They discovered cancer cells from the lymph had higher levels of a monounsaturated fatty acid known as oleic acid, which is the main component of olive oil.

They also found this monounsaturated fatty acid was incorporated into the membranes of cancer cells in the lymph. This diluted polyunsaturated fatty acids in the membranes of these cells, inhibiting the chemical reactions that lead to ferroptosis and protecting the cells.

This protective coating of oleic acid from the lymph thus allowed the cancer cells to safely enter the blood, travel to other locations, and form metastatic tumors.

This explains why cancer cells often form tumors first in lymph nodes before metastasizing to distant sites through the blood: They are able to load up on antioxidants in the lymph that protect the cells when they subsequently enter the blood.

"Now that we understand more about why cancer cells are most likely to metastasize initially through lymph, it raises the possibility of treating patients with drugs that target those protective mechanisms in the lymph to inhibit the early stages of metastasis," says Morrison.

Source:
Journal reference:

Ubellacker, J. M., et al. (2020) Lymph protects metastasizing melanoma cells from ferroptosis. Nature. doi.org/10.1038/s41586-020-2623-z.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Assessing the impact of gozetotide in PSMA-positive prostate cancer